- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00612066
Rosiglitazone in Treating Patients With Newly Diagnosed ACTH-Secreting Pituitary Tumor (Cushing Disease)
An Open Label, Multicenter Study Evaluating the Safety and Efficacy of Short Term (6 Weeks) Rosiglitazone Treatment in Patient's With Cushing's Disease
RATIONALE: Rosiglitazone may help pituitary tumor cells become more like normal cells, and to grow and spread more slowly.
PURPOSE: This phase II trial is studying how well rosiglitazone works in treating patients with newly diagnosed ACTH-secreting pituitary tumor (Cushing disease).
Study Overview
Detailed Description
OBJECTIVES:
Primary
- To assess the effect of rosiglitazone on biochemical control in patients with newly diagnosed ACTH-secreting pituitary tumor (Cushing disease).
Secondary
- To assess the effect of this drug on corticotrophin (CRH)-stimulated pituitary tumor ACTH secretion.
- To assess the overall safety and tolerability of this drug in these patients.
- To assess the overall quality of life of patients treated with this drug.
- Percentage of Reduction in 24-hour Urinary-free Cortisol Levels
OUTLINE: This is a multicenter study.
Patients receive oral rosiglitazone once daily for 7 weeks in the absence of disease progression or unacceptable toxicity.
Blood, urine, and saliva samples are collected periodically for laboratory studies. Inflammatory markers (C-reactive protein, interleukin-6 [IL-6], serum sialic acid, soluble intracellular and vascular adhesion molecules [sICAM-1, and sVCAM-1], and amyloid A) are measured at baseline and at the completion of study treatment; salivary cortisol and 24-hour urinary-free cortisol levels are measured at baseline and weekly during study treatment; dexamethasone suppression tests with serum cortisol and corticotrophin (CRH) stimulation test are performed at baseline and at the completion of study treatment; prolactin, insulin-like growth factor-1 (IGF1), thyroid function, and sex steroid hormones are measured at baseline and at the completion of study treatment; and dynamic pituitary function testing (arginine/growth hormone-releasing hormone [GHRH] testing to measure growth hormone secretion) is performed at baseline.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Los Angeles, California, United States, 90095-1781
- Jonsson Comprehensive Cancer Center at UCLA
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
DISEASE CHARACTERISTICS:
Clinically demonstrable ACTH-secreting pituitary tumor
- Pituitary tumor demonstrated on MRI with and without contrast AND/OR evidence of a central ACTH source following inferior petrosal sinus sampling
- Newly diagnosed disease
Biochemically active disease that is not adequately controlled, as demonstrated by the following standard criteria:
- Elevated 24-hour urinary-free cortisol levels on at least 2 separate 24-hour urine collections 1 week apart
- Lack of suppression of serum cortisol to < 1.8 μg/dL (at 8 am) following administration of 1 mg of dexamethasone at 11 pm the night before
- Measurable plasma ACTH levels
- Patient is hypercortisolemic and does not wish to receive alternate steroid-lowering therapy, such as ketoconazole and/or metyrapone
Patients with evidence of optic nerve or chiasm compression on post-operative MRI must have a normal visual field evaluation by Goldman perimetry
- No visual field abnormalities
Hypopituitarism* allowed, as evidenced by any or all of the following:
- Subnormal growth hormone (GH) response to arginine/growth hormone-releasing hormone (GHRH) testing (normal response is an increase of > 4 ng/mL)
- Low age-and sex-matched insulin-like growth factor-1 (IGF-1) levels
- Low thyroid-stimulating hormone (TSH) levels
- Low free triiodothyronine (T3) and free thyroxine (T4) levels
- Low estradiol levels
- Low luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels in postmenopausal female patients
- Low testosterone, LH, and FSH levels in male patients NOTE: *Patients who are diagnosed with hypopituitarism will initiate thyroid hormone replacement therapy prior to pituitary surgery as part of routine care. Other hormone replacement, such as sex steroids or growth hormone, will not be initiated during the study.
PATIENT CHARACTERISTICS:
- Not pregnant or nursing
- Fertile patients must use effective contraception (if oral contraception is used, it must be used for ≥ 2 months prior to, during, and for 1 month after completion of study therapy)
- No clinically significant renal, hematologic, or hepatic abnormalities
- No prior or concurrent medical condition that may interfere with the conduct of the study or the evaluation of its results, in the opinion of the investigator or the DSMB compliance officer
- No history of immunocompromise, including HIV positivity by ELISA and western blot
- No alcohol or drug abuse within the past 6 months
- No blood donation (≥ 400 mL) within the past 2 months
- No other active malignant disease within the past 5 years except for basal cell carcinoma or carcinoma in situ of the cervix
- No active or suspected acute or chronic uncontrolled infection
- No severe osteoporosis, defined as bone mineral density T scores < 2.5 standard deviations below age-matched controls
- No history of noncompliance to medical regimens
- Considered reliable
- Able to complete the entire study
PRIOR CONCURRENT THERAPY:
- More than 3 months since prior rosiglitazone or other thiazolidinedione
- No prior or concurrent radiotherapy for pituitary tumor
- More than 1 month since prior participation in any clinical investigation involving an investigational drug
- More than 30 days since prior unlicensed drugs
- No concurrent pituitary surgery
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Rosiglitazone
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Responders
Time Frame: 7 weeks
|
Definition of Treatment Response
|
7 weeks
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Endocrine System Diseases
- Endocrine Gland Neoplasms
- Hypothalamic Diseases
- Hyperpituitarism
- Pituitary Diseases
- Adenoma
- Pituitary Neoplasms
- ACTH-Secreting Pituitary Adenoma
- Pituitary ACTH Hypersecretion
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Rosiglitazone
Other Study ID Numbers
- CDR0000586468
- UCLA-0612080-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cushing's Disease
-
Sheffield Teaching Hospitals NHS Foundation TrustHRA PharmaCompleted
-
RECORDATI GROUPRecruitingEndogenous Cushing's SyndromeUnited States, Germany, France
-
Corcept TherapeuticsCompleted
-
Cortendo ABCompletedEndogenous Cushing's SyndromeUnited States, Bulgaria, Denmark, France, Greece, Hungary, Israel, Italy, Netherlands, Poland, Romania, Spain
-
Wuerzburg University HospitalCompletedEndogenous Cushing's SyndromeGermany
-
Cortendo ABCompletedEndogenous Cushing's SyndromeUnited States, Serbia, Denmark, Italy, Spain, Poland, Belgium, Bulgaria, Canada, Czechia, France, Germany, Israel, Netherlands, Turkey
-
University of OxfordAstraZenecaCompletedIatrogenic Cushing's DiseaseUnited Kingdom
-
Andrea M. IsidoriCompletedCushing's Syndrome CardiomyopathyItaly
-
Sparrow PharmaceuticalsActive, not recruitingCortisol; Hypersecretion | Cortisol Overproduction | Cushing's Syndrome I | Cushing Disease Due to Increased ACTH Secretion | Cortisol Excess | Ectopic ACTH SecretionUnited States, Bulgaria, Romania
-
Memorial Sloan Kettering Cancer CenterRecruitingCushing Syndrome | Cushing's Disease | Cushing DiseaseUnited States
Clinical Trials on rosiglitazone maleate
-
Dana-Farber Cancer InstituteNational Cancer Institute (NCI)Completed
-
Jonsson Comprehensive Cancer CenterNational Institutes of Health (NIH)TerminatedBrain and Central Nervous System TumorsUnited States
-
University of California, San FranciscoNational Cancer Institute (NCI)UnknownHead and Neck CancerUnited States
-
University of British ColumbiaCompletedHIV Infections | AtherosclerosisCanada
-
National Institute of Allergy and Infectious Diseases...CompletedHIV Infections | Hyperinsulinemia | LipodystrophyUnited States
-
GlaxoSmithKlineCompletedDiabetes Mellitus, Type 2United States
-
GlaxoSmithKlineCompletedDiabetes Mellitus, Type 2United States, Canada, Korea, Republic of, Australia, New Zealand, Mexico, Brazil
-
National Cancer Institute (NCI)Completed
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompletedAtherosclerosisUnited States, Russian Federation, Spain, Germany, Korea, Republic of, Sweden, Canada, Netherlands, Thailand, Hong Kong, Argentina, France, Mexico, Greece, Poland, Italy, India, Brazil, Latvia, Czech Republic